OKLAHOMA
Health Care Authority

State of Oklahoma SoonerCare Bavencio[®] (Avelumab) Prior Authorization Form

Member Name:	Date of Birth:	Member ID#:
	Drug Information	
Physician billing (HCPCS code:	de:) Start Date (or date of next dose):	
Dose:	Regimer	n:
	Billing Provider Inform	nation
SoonerCare Provider ID:	nerCare Provider ID: Provider Name:	
Provider Phone:	Provider Fax:	
	Prescriber Information	tion
Prescriber NPI:	Prescriber Name:	
Prescriber Phone:	Prescriber Fax:	Specialty:
	Criteria	
 Urothelial Carcinoma A. Is diagnosis locally B. Has disease progremonths of neoadjuv C. Will avelumab be us D. Has disease progremulation Renal Cell Carcinoma A. Is diagnosis advance B. Will avelumab be us C. Will avelumab be us 	atic MCC? Yes No atic MCC? Yes No advanced or metastatic uroth ssed during or following platin ant or adjuvant platinum-con- sed as maintenance therapy? ssed on a first-line platinum-co (RCC) sed RCC? Yes No sed as first-line treatment? Yes sed in combination with axitin ad above, please provide di	elial carcinoma? Yes <u>No</u> num-containing chemotherapy or within 12 taining chemotherapy? Yes <u>No</u> Yes <u>No</u> containing regimen? Yes <u>No</u>
 Date of last dose: Does member have any evid Has the member experience 	dence of progressive disease ad adverse drug reactions rela	e while on avelumab? Yes No ated to avelumab therapy? Yes No
Prescriber Signature:	tio modioally activity in the second second	_ Date:

I certify that the indicated treatment is medically necessary and all information is true and correct to the best of my knowledge.

Please do not send in chart notes. Specific information will be requested if necessary. Failure to complete this form in full will result in processing delays.

PLEASE PROVIDE THE INFORMATION REQUESTED AND RETURN TO:	CONFIDENTIALITY NOTICE
University of Oklahoma College of Pharmacy Pharmacy Management Consultants Product Based Prior Authorization Unit Fax: 1-800-224-4014 Phone: 1-800-522-0114 Option 4	This document, including any attachments, contains information which is confidential or privileged. If you are not the intended recipient, be aware that any disclosure, copying, distribution, or use of the contents of this information is prohibited. If you have received this document in error, please notify the sender immediately by telephone to arrange for the return of the transmitted documents or to verify their destruction.